Results 31 to 40 of about 11,874 (152)
Natalizumab for relapsing-remitting multiple sclerosis
Neurología (English Edition), 2011 Introduction: Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier and has been approved for the treatment of relapsing-remitting multiple sclerosis.
A. Horga, M. Tintoré
doaj +1 more source
The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
Therapeutic Advances in Neurological Disorders, 2017 Natalizumab, a monoclonal antibody that blocks lymphocyte infiltration in the central nervous system, is a valuable tool in the treatment of relapsing forms of multiple sclerosis (MS). In a phase III clinical trial comparing natalizumab with placebo over
Barry A. Singer
doaj +1 more source
Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis
European Journal of Case Reports in Internal Medicine, 2019 Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability.
Marina Rodrigues Lima +3 more
doaj +1 more source
High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients
Therapeutic Advances in Neurological Disorders, 2021 Aims: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion in natalizumab-treated patients. Background: Natalizumab is highly effective for the treatment of relapsing–remitting multiple sclerosis (RRMS), but its ...
Christopher M. Dwyer +16 more
doaj +1 more source
Clinical and Translational Medicine, 2018 Multiple sclerosis (MS) is a progressive immune-related disorder of the central nervous system leading to destruction of myelin sheaths. Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin which has been approved
Mehrdokht Mazdeh +3 more
doaj +1 more source
AboutOpenBackground: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS).
Roberto Bergamaschi +2 more
doaj +1 more source
Frontiers in Immunology, 2021 ObjectiveTo determine the transfer of the monoclonal antibody natalizumab into breastmilk and to evaluate drug and serum neurofilament light chain ((s)NfL) levels in natalizumab exposed pregnancies and lactation periods.MethodsEleven women with relapsing
Undine Proschmann +4 more
doaj +1 more source
Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort
Acta Médica Portuguesa, 2014 Introduction: Natalizumab is licensed as monotherapy for relapsing–remitting multiple sclerosis. Since pivotal studies showing natalizumab efficacy, several subsequent studies confirmed the reduction in annualized relapse rate and the slowing of ...
Ana Teresa Carvalho +2 more
doaj +1 more source
Drugs of Today, 2006 Medical therapeutics has entered a new and exciting era with the development of biological agents that target specific sites. In the studies performed to date, natalizumab, a humanized monoclonal antibody to alpha4 integrin, when administered intravenously at monthly intervals, appeared to be highly beneficial with respect to decreasing both relapse ...
europepmc +3 more sources
Patient monitoring during treatment with natalizumab (ORP-24) [PDF]
Neurology Letters, 2023 Natalizumab (Tysabri), a recombinant humanized monoclonal antibody selective for α4- integrin, is indicated for CIS, RRMS, and active SPMS in adults.
Zohreh Abna
doaj